Aarthi Shenoy

Aarthi Shenoy, MD, is program director of the Hematology and Oncology Fellowship and an attending hematologist at MedStar Washington Hospital Center. Her clinical and research interests focus on the diagnosis and treatment of cutaneous T-cell lymphomas as well as myelodysplastic syndromes.

Dr. Shenoy was a fellow at the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), where she led clinical protocols in stem cell transplant and myelodysplastic syndromes. While at the NIH, she was awarded a bench-to-bedside award in the area of stem cell transplant. She is currently a member of the American Society of Hematology, the American Society of Clinical Oncology and the International Society for Cutaneous Lymphomas.

She earned a medical degree from the University of Iowa, and completed a residency at the University of California, San Diego. Prior to completion of her fellowship, she was an assistant professor of Medicine at the University of California, San Diego, where she was involved with medical school and residency education. Dr. Shenoy completed a fellowship in Hematology and Oncology at the National Heart, Lung, and Blood Institute of the National Institutes of Health.

Research Interests

Dr. Shenoy's research interests include

  • Hematology
  • Oncology
  • Allogeneic stem cell transplantation
  • Hematological malignancies
  • Cutaneous T cell lymphoma
  • Leukemia
  • Myeloma
  • Bleeding and clotting problems

Selected Research

Evolution of the Donor T-Cell Repertoire in Recipients After Allogeneic Stem Cell Transplantation

After allogeneic stem cell transplantation (SCT), T lymphocyte function is reestablished from the donor's postthymic T cells. The immune repertoire and its relation to that of the donor, however, have not been characterized in long-term adult SCT survivors. In this article, published in Blood (2011;117:5250-5256), Dr. Shenoy collaborated with other researchers to study 21 healthy patients a median of 12 years after the patients had undergone myeloablative SCT for hematologic malignancy. The SCT survivors were found to have subtle defects in their immune profile that were consistent with defective thymic function but were compatible with normal health.

View Dr. Shenoy's publications on PubMed

Research Areas

  • Medical Education